Skip to main content
Clinical Trials/NCT04121013
NCT04121013
Unknown
Not Applicable

PREhospital Routage of Acute STroke Patients With Suspected Large Vessel Occlusion: Mothership Versus Drip and Ship, a Randomized Control Study in France (PRESTO-F)

University Hospital, Caen1 site in 1 country800 target enrollmentJanuary 30, 2021
ConditionsStroke

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Stroke
Sponsor
University Hospital, Caen
Enrollment
800
Locations
1
Primary Endpoint
Incremental cost-utility ratio
Last Updated
5 years ago

Overview

Brief Summary

Background: The outcome of ischemic stroke is related to the brain lesion volume and this volume of infarction is directly related to the time to reperfusion, which therefore depends on the time to initiation of therapy. Acute ischemic stroke is treated medically with the administration of intravenous rtPA, but recent randomized controlled trials have shown the efficacy of mechanical thrombectomy and is now the new gold standard in ischemic stroke. This new therapeutic strategy has created two possibilities for pre-hospital decision-making: i/ transport the patient directly to the nearest stroke unit to receive alteplase and then if indicated perform a thrombectomy (drip and ship) or ii/ bypassing thrombolysis centres in favour of endovascular thrombectomy (mothership).

Objective: To compare cost/effectiveness of transfer to the closest local stroke centre or telemedicine hub to direct transfer to the comprehensive stroke cent(CSC) in patients acute stroke with suspected large vessel occlusion.

Medical and economic expected impact: We hypothesize that direct transportation to CSC is associated with better clinical outcome in case of acute ischaemic stroke due to intracranial large vessel occlusion. However, we have to demonstrate that this approach is not associated with time from onset harm in patients not eligible to mechanical thrombectomy.

Detailed Description

Design: Multicenter, two-arm, prospective, open, blinded end-point (PROBE), randomized, clinical trial Primary endpoint: Incremental cost-utility ratio at 12 months. Secondary endpoints: modified Rankin scale and EuroQoL5D scale at 3 months. Eligibility criteria: A call to the emergency medical assistance service, 18 years and older, severe acute stroke symptoms, transportation time from scene to the CSC longer than time to go to the nearest stroke unit or telemedicine hub, transportation time from scene to the CSC compatible with IV thrombolysis, known time from onset, RACE score (assessed by medical emergency technicians) ≥5. Experimental arm: direct transportation to the CSC. Control arm: transfer to the closest local stroke centre or telemedicine hub. Sample size: 800 patients, 400 for each arm.

Registry
clinicaltrials.gov
Start Date
January 30, 2021
End Date
January 2022
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • A call to the emergency medical assistance service;
  • age\> 18y,
  • known time of stroke onset;
  • transportation time from scene to the CSC longer than time to go to the nearest stroke unit or telemedicine hub;
  • transportation time from scene to the CSC compatible with IV thrombolysis;
  • known time from onset, RACE score ≥5.

Exclusion Criteria

  • transportation time from scene to the CSC longer than time to go to the nearest stroke unit or telemedicine hub.
  • no ambulance available
  • bedridden patient

Outcomes

Primary Outcomes

Incremental cost-utility ratio

Time Frame: 12 months

Incremental cost-utility ratio (ICUR) at 12 months, defined as the ratio of the incremental cost of management by transfer to a CSC with MT (compared to the control arm "local PSC") to the gain in healthy survival (quality adjusted life years, QALYs).

Secondary Outcomes

  • modified Rankin scale score(90 days)

Study Sites (1)

Loading locations...

Similar Trials